Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)
← catalyst calendarSponsored by Annexon, Inc. (industry) · ANNX — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
17actual
Sites
8
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-25
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-01-15 | actual | When the study began enrolling |
| Primary completion | 2024-01-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2024-04-23 | actual | The whole study's end, after follow-up |
| First posted | 2020-09-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-01-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Amyotrophic Lateral Sclerosis
Intervention
- Drug: ANX005
Primary outcome
what the primary-completion date above is the date OFNumber of Participants Who Experienced Treatment-Emergent Adverse Events
measured Up to Week 36
Related
ANNX's other studiesmost recently updated first
- An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease Phase 2 · Completed
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA) Phase 2 · Completed
- An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) Phase 3 · Recruiting
- A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) Phase 3 · Active, not recruiting
- Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome Phase 3 · Completed
Permalink · ANNX's whole pipeline · Catalyst calendar · Every registered study · What changed